S. H. Subramony

University of Minnesota — United States

Neuroscience · Life Sciences

45h-index10.9kcitations222works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic Neurodegenerative Diseases(160), Mitochondrial Function and Pathology(96), Neurological disorders and treatments(41), Parkinson's Disease Mechanisms and Treatments(29), Muscle Physiology and Disorders(19)

Publications221 total

Value of <scp>MRI</scp> Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3
Annals of Clinical and Translational Neurology·2026Open Access
Cognitive impairment in SCA3: A multi-center cohort study with demographic, imaging, and biomarker correlates
Neurobiology of Disease·2026Open Access
Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study
PLoS ONE·2025Open Access
Quantitative Magnetic Resonance Imaging of the Forearm in Myotonic Dystrophy Type 1
Tomography·2025Open Access
Friedreich Ataxia
Pediatric Neurology·2025
Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3
Brain·2025Open Access
357PLong-term vatiquinone treatment slows Friedreich’s ataxia disease progression relative to FACOMS natural history
Neuromuscular Disorders·2025
234PLong-term use of omaveloxolone in patients with Friedreich ataxia: up to 5 years of natural history propensity score matching from the MOXIe OLE
Neuromuscular Disorders·2025
391PA prospective longitudinal observational study in myotonic dystrophy type 1 (DM1): from clinical outcomes and endpoints to clinical trial design
Neuromuscular Disorders·2025
Prevalence, Severity, and Progression of Cerebellar Cognitive-Affective Syndrome in Patients With Spinocerebellar Ataxias
Neurology·2025· 2 citedOpen Access
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1): protocol of an international natural history study
2025Open Access
Propensity-matched analysis comparing omaveloxolone treatment to Friedreich ataxia natural history data: a plain language summary
Future Neurology·2025Open Access
Automated Deep Learning–based Segmentation of the Dentate Nucleus Using Quantitative Susceptibility Mapping MRI
Radiology Artificial Intelligence·2025
Fixel‐Based Analysis of Diffusion Imaging as a Quantitative Marker of Disease State in Spinocerebellar Ataxia
Annals of Clinical and Translational Neurology·2025· 1 citedOpen Access
Correction: A natural history study to track brain and spinal cord changes in individuals with Friedreich’s ataxia: TRACK-FA study protocol
PLoS ONE·2025Open Access
Suicidal Ideation in Spinocerebellar Ataxia
Journal of Neuropsychiatry·2025
Current clinical applications of AAV-mediated gene therapy
Molecular Therapy·2025· 35 citedOpen Access
Respiratory Function Correlates With Swallowing Related Quality of Life Measures in Patients With Friedreich's Ataxia
American Journal of Respiratory and Critical Care Medicine·2025
Neuroimaging Biomarkers for Friedreich Ataxia: A Cross‐Sectional Analysis of the <scp>TRACK</scp>‐<scp>FA</scp> Study
Annals of Neurology·2025· 3 citedOpen Access
Correction: A natural history study to track brain and spinal cord changes in individuals with Friedreich’s ataxia: TRACK-FA study protocol
PLoS ONE·2025Open Access
page 1 of 12Next →

Frequent Co-authors

Susan Perlman(20), George Wilmot(18), Tetsuo Ashizawa(15), David R. Lynch(15), Christopher M. Gómez(14), Theresa A. Zesiewicz(14), Katherine D. Mathews(13), Jennifer Farmer(10), Khalaf Bushara(10), Martin B. Delatycki(9), Henry L. Paulson(6), Jeremy D. Schmahmann(6), J. Chad Hoyle(5), Sheng‐Han Kuo(5), Sarah H. Ying(5), Karla P. Figueroa(5), Alicia Brocht(5), Sylvia Boesch(4), Wolfgang Nachbauer(4), Paola Giunti(4)